Plasma microbial translocation, the composition of the microbiome and environmental factors may influence the development of autoantibodies in patients with systemic lupus erythematosus (SLE), according to a study comparing SLE patients with their first-degree relatives and unrelated, healthy controls.
PCSK9 Inhibitors May Lower Cholesterol in Patients with Statin-Associated Immune-Mediated Necrotizing Myopathy
A 2019 study demonstrated the benefit of a newer drug class, PCSK9 inhibitors, to help lower cholesterol in patients with statin-associated immune-mediated necrotizing myopathy…
Rituximab as Maintenance Therapy for Difficult-to-Treat SLE
For some patients with systemic lupus erythematosus, regular repeated treatment with rituximab may prevent disease flare, according to a study from Cassia et al.
Biologics May Prevent Cardiovascular Events in RA Patients
RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…
Are ANAs More Prevalent in the U.S. Now Than in the Past?
According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…
Researchers Discuss Viability of Rheumatology Education During the COVID‐19 Pandemic
In a matter of weeks, the COVID‑19 crisis has totally upended clinical medicine and the practice of rheumatology. Our old ways of seeing patients in person, precepting fellows in clinic or on the consult service, and leading in-person interactive teaching rounds are gone for now and possibly for good. But how can we replace these…
9/11 Survivors at Increased Risk for Autoimmune Disease
Miller-Archie et al. set out to determine whether dust exposure and PTSD are associated with an increased risk of systemic autoimmune disease in a 9/11-exposed cohort not included in previous studies of members of the Fire Department of New York and whether this association differs between 9/11 responders and community members.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »